Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Prochazka, KT; Neumeister, P.
Chronic lymphocytic leukaemia-what is new and notable in 2021, with a special focus on COVID-19.
Memo. 2021; 1-4
Doi: 10.1007/s12254-021-00735-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Prochazka Katharina
- Co-Autor*innen der Med Uni Graz
-
Neumeister Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
- Find related publications in this database (Keywords)
-
Chronic lymphocytic leukemia
-
Targeted therapy
-
Coronavirus disease 2019
-
Bruton tyrosin kinase
-
Bcl2-inhibitor